Generic Version
- All
- News
- Videos
-
Ozempic Copycats Arrive: From Rs 11,000 To Rs 3,000, How Patent Expiry Is Reshaping Diabetes Treatment
- Saturday March 21, 2026
- Health | Reported by Tanushka Dutta
With patent protection ending, Indian companies have moved quickly to introduce lower-cost versions with monthly therapy expected at around Rs 3,000 to Rs 4,000 for initial doses
-
www.ndtv.com
-
Weight Loss Injection For ₹900? Three Pharma Firms Launch Affordable Semaglutide, Check Prices
- Saturday March 21, 2026
- Feature | Edited by Nikhil Pandey
Indian pharmaceutical companies have launched affordable versions of semaglutide injections following a patent expiry, significantly lowering costs for diabetes and weight management treatment and improving access for millions of patients.
-
www.ndtv.com
-
Indian Pharma Giants Launch Low-Cost Generic Semaglutide Injections For Diabetes, Weight Management
- Saturday March 21, 2026
- Health | Indo-Asian News Service
New Delhi, March 21 (IANS) Three Indian pharmaceutical companies have launched generic versions of semaglutide injections, after the drug’s patent expired, offering lower‑cost options for patients managing Type 2 diabetes and obesity.
-
www.ndtv.com
-
Semaglutide Patent Expires: Will Diabetes, Weight-Loss Treatment Become More Accessible For Patients?
- Friday March 20, 2026
- Health | Written by Dr Hari Kishan Boorugu
Patent expiry does not signal a change in the medicine itself. Rather, it marks the beginning of wider competition, which typically leads to price reductions and improved availability.
-
www.ndtv.com
-
Affordable Semaglutide Is Coming: Should You Be Worried About Drug Safety, Health Risks And Side Effects?
- Thursday March 19, 2026
- Health | Written by Sambhav Kumar
India's healthcare landscape will change as semaglutide patents expire in 2026, allowing over 50 generic versions to enter the market and improve access for diabetes and obesity treatment.
-
www.ndtv.com
-
Ozempic's Key Molecule To Go Off-Patent: What Changes Now?
- Thursday March 19, 2026
- Health | Reported by Tanushka Dutta
Patent protections on semaglutide, developed by Novo Nordisk, will lapse on March 20, opening the door for domestic pharmaceutical companies to manufacture and sell their own versions of the drug.
-
www.ndtv.com
-
From Diabetes To Weight Loss: How Semaglutide Became The Blockbuster Behind Ozempic, Wegovy
- Wednesday March 18, 2026
- Health | Written by Shreya Goswami
From a diabetes drug to a global weight-loss phenomenon, semaglutide has reshaped modern medicine. As patents expire, cheaper versions may expand access, raising questions about affordability, safety and long-term impact.
-
www.ndtv.com
-
What Are Semaglutide Generics? Here's Why They Matter More In India Now
- Tuesday March 17, 2026
- Health | Written by Sambhav Kumar
Semaglutide works by imitating the natural hormone glucagon-like peptide-1 (GLP-1), which plays a key role in managing blood sugar.
-
www.ndtv.com
-
50+ Branded Semaglutide Generics To Enter India As Diabetes Drug Patent Expires In March 2026
- Monday March 16, 2026
- Health | Written by Sambhav Kumar
Semaglutide patent in India expires in March 2026, enabling over 50 branded generic versions to enter the market, likely reducing treatment costs for diabetes and obesity patients.
-
www.ndtv.com
-
Cheap Generic Ozempic To Hit India: Patent Exit Sparks Weight-Loss Drug Boom
- Wednesday March 18, 2026
- Health | Satviki Sanjay, Bloomberg
Swati Pradhan sees about 12 obesity patients a day at her clinic in southern Mumbai. She expects this number to at least double from this month as Indian drug makers prepare to launch off-patent versions of Novo Nordisk A/S's blockbuster weight.
-
www.ndtv.com
-
Ozempic Copycats Arrive: From Rs 11,000 To Rs 3,000, How Patent Expiry Is Reshaping Diabetes Treatment
- Saturday March 21, 2026
- Health | Reported by Tanushka Dutta
With patent protection ending, Indian companies have moved quickly to introduce lower-cost versions with monthly therapy expected at around Rs 3,000 to Rs 4,000 for initial doses
-
www.ndtv.com
-
Weight Loss Injection For ₹900? Three Pharma Firms Launch Affordable Semaglutide, Check Prices
- Saturday March 21, 2026
- Feature | Edited by Nikhil Pandey
Indian pharmaceutical companies have launched affordable versions of semaglutide injections following a patent expiry, significantly lowering costs for diabetes and weight management treatment and improving access for millions of patients.
-
www.ndtv.com
-
Indian Pharma Giants Launch Low-Cost Generic Semaglutide Injections For Diabetes, Weight Management
- Saturday March 21, 2026
- Health | Indo-Asian News Service
New Delhi, March 21 (IANS) Three Indian pharmaceutical companies have launched generic versions of semaglutide injections, after the drug’s patent expired, offering lower‑cost options for patients managing Type 2 diabetes and obesity.
-
www.ndtv.com
-
Semaglutide Patent Expires: Will Diabetes, Weight-Loss Treatment Become More Accessible For Patients?
- Friday March 20, 2026
- Health | Written by Dr Hari Kishan Boorugu
Patent expiry does not signal a change in the medicine itself. Rather, it marks the beginning of wider competition, which typically leads to price reductions and improved availability.
-
www.ndtv.com
-
Affordable Semaglutide Is Coming: Should You Be Worried About Drug Safety, Health Risks And Side Effects?
- Thursday March 19, 2026
- Health | Written by Sambhav Kumar
India's healthcare landscape will change as semaglutide patents expire in 2026, allowing over 50 generic versions to enter the market and improve access for diabetes and obesity treatment.
-
www.ndtv.com
-
Ozempic's Key Molecule To Go Off-Patent: What Changes Now?
- Thursday March 19, 2026
- Health | Reported by Tanushka Dutta
Patent protections on semaglutide, developed by Novo Nordisk, will lapse on March 20, opening the door for domestic pharmaceutical companies to manufacture and sell their own versions of the drug.
-
www.ndtv.com
-
From Diabetes To Weight Loss: How Semaglutide Became The Blockbuster Behind Ozempic, Wegovy
- Wednesday March 18, 2026
- Health | Written by Shreya Goswami
From a diabetes drug to a global weight-loss phenomenon, semaglutide has reshaped modern medicine. As patents expire, cheaper versions may expand access, raising questions about affordability, safety and long-term impact.
-
www.ndtv.com
-
What Are Semaglutide Generics? Here's Why They Matter More In India Now
- Tuesday March 17, 2026
- Health | Written by Sambhav Kumar
Semaglutide works by imitating the natural hormone glucagon-like peptide-1 (GLP-1), which plays a key role in managing blood sugar.
-
www.ndtv.com
-
50+ Branded Semaglutide Generics To Enter India As Diabetes Drug Patent Expires In March 2026
- Monday March 16, 2026
- Health | Written by Sambhav Kumar
Semaglutide patent in India expires in March 2026, enabling over 50 branded generic versions to enter the market, likely reducing treatment costs for diabetes and obesity patients.
-
www.ndtv.com
-
Cheap Generic Ozempic To Hit India: Patent Exit Sparks Weight-Loss Drug Boom
- Wednesday March 18, 2026
- Health | Satviki Sanjay, Bloomberg
Swati Pradhan sees about 12 obesity patients a day at her clinic in southern Mumbai. She expects this number to at least double from this month as Indian drug makers prepare to launch off-patent versions of Novo Nordisk A/S's blockbuster weight.
-
www.ndtv.com